INT168503

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 5.12
Pain Relevance 0.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (FUS) cell death (FUS) nucleolus (FUS)
RNA binding (FUS) nucleus (FUS) intracellular (FUS)
FUS (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 5 83.16 Quite High
Pain 5 81.84 Quite High
methotrexate 22 5.00 Very Low Very Low Very Low
headache 6 5.00 Very Low Very Low Very Low
adenocard 4 5.00 Very Low Very Low Very Low
Arthritis 4 5.00 Very Low Very Low Very Low
cva 3 5.00 Very Low Very Low Very Low
fibrosis 3 5.00 Very Low Very Low Very Low
abdominal pain 3 5.00 Very Low Very Low Very Low
Central nervous system 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Tumor Lysis Syndrome 72 100.00 Very High Very High Very High
Cancer 64 99.44 Very High Very High Very High
Testicular Cancer 1 99.36 Very High Very High Very High
Solid Tumor 9 98.28 Very High Very High Very High
Congenital Anomalies 7 98.12 Very High Very High Very High
Hyperuricemia 63 95.44 Very High Very High Very High
Disease 18 95.28 Very High Very High Very High
Sarcoma 6 94.92 High High
Lymphatic System Cancer 6 94.40 High High
Thrombosis 2 91.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Cytogenetically, the lesion has also been associated with the t (7,16) (q33;p11) translocation, with the characteristic resultant FUS and CREB3L2 fusion gene.
FUS Binding (associated) of
1) Confidence 0.29 Published 2010 Journal J Foot Ankle Surg Section Abstract Doc Link 20510633 Disease Relevance 0.77 Pain Relevance 0.08
TLS has been reported in association with several tumors: haematologic malignancies and bulky solid tumours. 32,33-35
TLS Binding (association) of associated with cancer, solid tumor and tumor lysis syndrome
2) Confidence 0.07 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 1.74 Pain Relevance 0.04
Already before 2002, when Food and Drugs Administration (FDA) of US has approved the use of urate oxidase for the management of paediatric patients at risk for TLS (Tumor Lysis Syndrome) 26, urate oxidase was used for this purpose with good efficacy. 13,14,27-30 Currently US FDA does not approve its use in adult, instead EU FDA has approved it in children and adult. 19
TLS Binding (risk) of associated with tumor lysis syndrome
3) Confidence 0.07 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 0.77 Pain Relevance 0
FUS-X binds to the peptidyltransferase catalytic center on ribosomes and blocks the extension of the peptide chain [120].
FUS-X Binding (binds) of
4) Confidence 0.01 Published 2008 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2635619 Disease Relevance 0.45 Pain Relevance 0
Early recognition of patients at high risk for acute TLS may allow the initiation of prophylactic measures.
TLS Binding (recognition) of associated with tumor lysis syndrome
5) Confidence 0.01 Published 2006 Journal Crit Care Section Body Doc Link PMC1550893 Disease Relevance 1.39 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox